Engineered Alpha-Synuclein Mouse Models Reshape Parkinson’s Therapy Testing
A new review details how engineered alpha-synuclein mouse models with defined biochemical defects are transforming Parkinson's disease therapy development.
Tag: Synucleinopathy
Beta-Blockers and Parkinson’s Disease Progression Unveiled
In recent years, the search for therapeutic strategies that could slow or prevent the progression of Parkinson’s disease (PD) has ...
POPULAR NEWS
-
Nursing Student Needlestick Reporting Relies on Supervisor Support Rather Than Systems
-
Cross-Sectional Model Identifies Musculoskeletal Injury Risk in Clinical Nurses
-
Biologging Devices Yield Minimal Short-Term Effects on Three European Toad Species
-
Machine Learning Framework Optimizes Seismic Retrofitting for Aging Railway Viaduct Columns